BRAF and melanoma: First-lineIpilimumab and nivolumab is a preferred option for all patients regardless of BRAFstatus.First-line nivolumabor pembrolizumab is also recommended.BRAF/MEKi combination therapy is also an option in the first line for patientswith BRAFV600-mutant melanoma.Clinical trial